This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
I still recall the metric that was drilled into me back then: hit $50 million in revenue and a few back-to-back years of profitability and you, too, can go public. The benefits of going public are significant. This contrasts with the rigid timelines and standardized processes associated with IPOs.
Stock prices and valuations of many leading public SaaS companies have fallen drastically from the beginning of 2022—but while that will affect the private market, it does not necessarily spell doom and gloom. This post will examine the current state of public SaaS company valuations and what it means for private companies.
Novartis announced plans to spin off its generics and biosimilars division into a publicly traded stand-alone company. We also are aware of a number of deals where buyers walked away late in discussions due to unexpected FDA or other regulatory risks, the potential impact of a transaction on profitability or the lack of board support.
For earlier-stage target companies that may lack adequate proof of concept, potential buyers continue to use collaborations combined with options to acquire. For example, in 2019, Genentech and Convelo Therapeutics entered into a structured acquisition deal to implement a strategic partnership and exclusive collaboration.
Many marketing departments work in silos – I encouraged cross-functional collaboration with sales, product development, and customer success. This collaborative approach helped ensure marketing efforts aligned with business objectives and the organization was working towards a common goal.
Strategic buyers These types of buyers run the gamut; they can be publicly traded or privately owned software companies. Some will push to maximize profit quickly. When you’re selling your company, both represent appealing options, depending on what you want to get out of the sale.
We organize all of the trending information in your field so you don't have to. Join 38,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content